

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 14, 2013

CORONADO BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
**(State or Other Jurisdiction
of Incorporation)**

001-35366
**(Commission
File Number)**

20-5157386
**(IRS Employer
Identification No.)**

24 New England Executive Park, Burlington, MA
(Address of Principal Executive Offices)

01803
(Zip Code)

Registrant's Telephone Number, Including Area Code: (781) 652-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On March 14, 2013, Coronado Biosciences, Inc., a Delaware corporation, issued a press release containing certain financial results for its fourth quarter and full year ended December 31, 2012. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

As provided in General Instruction B.2 of SEC Form 8-K, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated March 14, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: March 14, 2013

/s/ Dale Ritter

Name: Dale Ritter

Title: Senior Vice President, Finance



**CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED
DECEMBER 31, 2012**

Burlington, MA – March 14, 2013 – Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2012.

“We made significant strides in 2012 towards increasing the value of our product candidates and expanded our pipeline of clinical trials,” said Dr. Harlan F. Weisman, Coronado’s Chairman and CEO. “It was an important year for Coronado in that we signed a collaboration agreement with Dr. Falk Pharma GmbH (Falk) and Ovamed GmbH (Ovamed) for the development of TSO (*Trichuris suis* ova or CNDO-201) for Crohn’s disease, initiated TRUST-I, our phase 2 clinical trial of TSO in Crohn’s disease, and initiated two investigator-initiated studies evaluating TSO in ulcerative colitis and autism spectrum disorders. Additionally, we commenced a phase 1/2 trial of CNDO-109 activated allogeneic natural killer (NK) cells, our second technology, in acute myeloid leukemia (AML). From a financial standpoint, in 2012, we conducted our first public offering with net proceeds of \$26.5 million and secured a \$15.0 million loan facility with Hercules Technology Growth Capital to further support our clinical development efforts.

“This is an exciting time for Coronado. We believe results from the two phase 2 trials in Crohn’s disease, and possibly data from the autism study and the recently announced investigator-initiated psoriasis study, have the potential to positively validate the hygiene hypothesis and our mission to provide life-changing therapies for autoimmune diseases during 2013. We are committed to continuing our momentum throughout 2013, starting with the initiation of several more investigator-initiated studies for TSO in various autoimmune diseases in 2013.”

Financial Highlights:

- Coronado reported a net loss of \$8.7 million, or \$0.36 per share, for the fourth quarter of 2012 compared to a net loss of \$6.7 million, or \$0.52 per share, for the fourth quarter of 2011. For the year ended December 31, 2012, Coronado reported a net loss of \$ 27.6 million, or \$1.27 per share, compared to a net loss of \$36.4 million, or \$4.74 per share before the common stock dividend to Series A Preferred Stockholders, for 2011.
- Research and development expenses were \$17.5 million for the year ended December 31, 2012, compared to \$8.6 million for 2011. General and administrative expenses totaled \$8.7 million for the year ended December 31, 2012, compared to \$5.8 million for 2011. In 2012, R&D included expenses related to the TSO clinical program and G&A included expenses related to the company’s infrastructure growth and increased business activity.
- At December 31, 2012, Coronado’s cash and cash equivalents totaled \$40.2 million. During the first quarter of 2013, and through March 13, 2013, the company sold an aggregate of approximately 1.4 million shares of common stock under an at market issuance facility for net proceeds of \$10.5 million.

Recent Corporate and Scientific Highlights:

- Initiated phase 1/2 trial of CNDO-109 activated allogeneic NK cells in AML
- Signed Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to evaluate TSO for the treatment of ulcerative colitis in a multi-center phase 2 clinical trial that will be conducted by the NIAID-funded Autoimmunity Centers of Excellence (ACE)
- Acquired manufacturing rights to TSO from Ovamed, for North America, South America, and Japan, Coronado's licensed territory and, in conjunction therewith, acquired a lease agreement to establish a manufacturing facility in Woburn, MA to produce TSO
- Appointed Dr. Harlan F. Weisman, a director for the company since August 2012, Chairman and CEO
- Signed Research Collaboration and License Agreement with Freie Universität Berlin for secretory products of *Trichuris suis*
- Commenced an investigator-initiated study evaluating TSO in psoriasis

Upcoming Events:

- ROTH Capital Partners 25th Annual Growth Stock Conference, March 18, 2013
- Analyst Event, April 9, 2013

Conference Call and Webcast Information

Coronado management will review its fourth quarter and year-end financial results and development programs via conference call and webcast today at 8:30 AM EDT. To participate in the conference call, please dial 877-312-5413 (toll free from the US and Canada), or 253-237-1511 (for international callers). Investors may also access a live audio webcast of the call at www.coronadobiosciences.com on the Events & Webcasts page.

A replay of the webcast will be available shortly after the conclusion of the call. The webcast archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until March 24, 2013. The audio replay can be accessed by dialing 855-859-2056 (toll free from the US and Canada), or 404-537-3406 (for international callers) and entering Event ID 15400780.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (*Trichuris suis* ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include,

but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to the cost, timing, and results of research and development activities, uncertainties relating to preclinical and clinical testing, our ability to attract, integrate and retain key personnel, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters, our dependence on third party suppliers, and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Lucy Lu, MD, Executive Vice President & Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; ir@coronadobio.com

Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Susan Forman
Dian Griesel Inc.
212-825-3210; susan@dgicomm.com

CORONADO BIOSCIENCES, INC. AND SUBSIDIARY

(A development stage enterprise)

Consolidated Balance Sheets

(\$ in thousands)

	December 31, 2012	December 31, 2011
ASSETS		
Cash and cash equivalents	\$ 40,199	\$ 23,160
Prepaid and other current assets	<u>393</u>	<u>215</u>
Total current assets	40,592	23,375
Property & equipment net	51	—
Other	<u>349</u>	<u>—</u>
Total Assets	<u>\$ 40,992</u>	<u>\$ 23,375</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities	\$ 5,132	\$ 3,493
Note payable, non-current	12,386	750
Other long-term liabilities	<u>1,441</u>	<u>—</u>
Total Liabilities	18,959	4,243
Stockholders' Equity	<u>22,033</u>	<u>19,132</u>
Total Liabilities and Stockholders' Equity	<u>\$ 40,992</u>	<u>\$ 23,375</u>

CORONADO BIOSCIENCES, INC. AND SUBSIDIARY

(A development stage enterprise)

Consolidated Statements of Operations

(\$ in thousands except for share amounts)

	For the three months ended December 31,		For the twelve months ended December 31,	
	2012	2011	2012	2011
Operating expenses:				
Research and development	\$ 4,585	\$ 3,442	\$ 17,468	\$ 8,583
General and administrative	2,671	1,790	8,665	5,755
In-process research and development	1,043	—	1,043	20,706
Loss from operations	(8,299)	(5,232)	(27,176)	(35,044)
Interest income	84	54	236	165
Interest expense	(449)	(19)	(670)	(74)
Warrant expense	—	(1,522)	—	(1,407)
Net loss	(8,664)	(6,719)	(27,610)	(36,360)
Common Stock dividend to Series A Convertible Preferred Stockholders	—	—	—	(5,861)
Net loss attributed to Common Stockholders	(\$ 8,664)	(\$ 6,719)	(\$ 27,610)	(\$ 42,221)
Basic and diluted net loss per common share	(\$ 0.36)	(\$ 0.52)	(\$ 1.27)	(\$ 5.51)
Weighted average common shares outstanding—basic and diluted	24,385,981	12,901,980	21,654,984	7,662,984